Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Moodys
Deloitte
Accenture
Cantor Fitzgerald
Chubb
Argus Health
Queensland Health
Mallinckrodt

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202236

« Back to Dashboard

NDA 202236 describes DYMISTA, which is a drug marketed by Mylan Speciality Lp and is included in one NDA. It is available from two suppliers. There are four patents protecting this drug and one Paragraph IV challenge. Additional details are available on the DYMISTA profile page.

The generic ingredient in DYMISTA is azelastine hydrochloride; fluticasone propionate. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the azelastine hydrochloride; fluticasone propionate profile page.
Summary for 202236
Tradename:DYMISTA
Applicant:Mylan Speciality Lp
Ingredient:azelastine hydrochloride; fluticasone propionate
Patents:4
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 202236
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DYMISTA azelastine hydrochloride; fluticasone propionate SPRAY, METERED;NASAL 202236 NDA Meda Pharmaceuticals 0037-0245 N 0037-0245-06
DYMISTA azelastine hydrochloride; fluticasone propionate SPRAY, METERED;NASAL 202236 NDA Meda Pharmaceuticals 0037-0245 N 0037-0245-23

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;NASALStrengthEQ 0.125MG BASE/SPRAY;0.05MG/SPRAY
Approval Date:May 1, 2012TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Feb 20, 2018
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Regulatory Exclusivity Expiration:Aug 20, 2018
Regulatory Exclusivity Use:PEDIATRIC EXCLUSIVITY
Patent:➤ Try a Free TrialPatent Expiration:Feb 29, 2024Product Flag?Substance Flag?Delist Request?Y

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
US Army
Federal Trade Commission
Cerilliant
Healthtrust
Fuji
Cipla
Teva
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.